Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 1/2004

01.02.2004 | Review

Radiation and breast cancer: a review of current evidence

verfasst von: Cécile M Ronckers, Christine A Erdmann, Charles E Land

Erschienen in: Breast Cancer Research | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

This paper summarizes current knowledge on ionizing radiation-associated breast cancer in the context of established breast cancer risk factors, the radiation dose–response relationship, and modifiers of dose response, taking into account epidemiological studies and animal experiments. Available epidemiological data support a linear dose–response relationship down to doses as low as about 100 mSv. However, the magnitude of risk per unit dose depends strongly on when radiation exposure occurs: exposure before the age of 20 years carries the greatest risk. Other characteristics that may influence the magnitude of dose-specific risk include attained age (that is, age at observation for risk), age at first full-term birth, parity, and possibly a history of benign breast disease, exposure to radiation while pregnant, and genetic factors.
Literatur
1.
Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2: 533-543. 10.1016/S1470-2045(01)00486-7.PubMedCrossRef
2.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin. 2004, 54: 8-29.PubMedCrossRef
3.
Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: Hormonal risk factors, breast tissue age and the age-incidence of breast cancer. Nature. 1983, 303: 767-770. 10.1038/303767a0.PubMedCrossRef
4.
5.
MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S: Age at first birth and breast cancer risk. Bull Wld Hlth Org. 1970, 43: 209-221.
6.
Henderson BE, Ross RK, Pike MC, Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res. 1982, 42: 3232-3239.PubMed
7.
Clifton KH, Sridharan BN, Douple EB: Mammary carcinogenesis-enhancing effect of adrenalectomy in irradiated rats with pituitary tumor MtT-F4. J Natl Cancer Inst. 1975, 55: 485-487.PubMed
8.
Pathak DR: Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology [Editorial]. Cancer Causes Control. 2002, 13: 295-298. 10.1023/A:1015282916368.PubMedCrossRef
9.
Liu Q, Wuu J, Lambe M, Hsieh S-H, Ekbom A, Hsieh C-C: Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Causes Control. 2002, 13: 299-305. 10.1023/A:1015287208222.PubMedCrossRef
10.
Endogenous Hormones and Breast Cancer Collaborative Group (EHBCCG): Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002, 94: 606-616.CrossRef
11.
Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC): Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996, 347: 1713-1727. 10.1016/S0140-6736(96)90806-5.CrossRef
12.
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD: Post-menopausal hormone replacement therapy: scientific review. JAMA. 2002, 288: 872-881. 10.1001/jama.288.7.872.PubMedCrossRef
13.
Page DP, Dupont WD: Benign breast disease: indicators of increased breast cancer risk. Cancer Detect Prev. 1992, 16: 93-97.PubMed
14.
Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 7: 1133-1144.PubMed
15.
Sasco AJ, Kaaks R, Little RE: Breast cancer: occurrence, risk factors and hormone metabolism. Expert Rev Anticancer Ther. 2003, 4: 546-562.CrossRef
16.
Trichopoulos D: Intrauterine environment, mammary gland mass and breast cancer risk. Breast Cancer Res. 2003, 5: 42-44. 10.1186/bcr555.PubMedCrossRef
17.
Elias SG, Peeters PH, Grobbee DE, van Noord PA: Breast cancer risk after caloric restriction during the 1944–1945 Dutch famine. J Natl Cancer Inst. 2004, 96: 539-456.PubMedCrossRef
18.
De Stavola BL, dos Santos Silva I, McCormack V, Hardy RJ, Kuh DJ, Wadsworth MEJ: Childhood growth and breast cancer. Am J Epidemiol. 2004, 159: 674-682. 10.1093/aje/kwh097.CrossRef
19.
Pharoah PDP, Day NE, Duffy S, Easton DF, Ponder BAJ: Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997, 71: 800-809.PubMedCrossRef
20.
Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC): Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001, 358: 1389-1399. 10.1016/S0140-6736(01)06524-2.CrossRef
21.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000, 343: 78-85. 10.1056/NEJM200007133430201.PubMedCrossRef
22.
Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC: Frequency of breast cancer attributable to BCRA1 in a population-based series of American women. JAMA. 1998, 279: 915-921. 10.1001/jama.279.12.915.PubMedCrossRef
23.
24.
DeMichele A, Weber B: Inherited genetic factors. In Disease of the Breast. Edited by: Harris JR, Lippman ME, Morrow M, Osborne CK. 2000, New York: Lippincott Williams & Wilkins, 2
25.
Powell SN, Willers H, Xia F: BCRA2 keeps Rad51 in line: high-fidelity homologous recombination prevents breast and ovarian cancer?. Mol Cell. 2002, 10: 1262-1263. 10.1016/S1097-2765(02)00789-X.PubMedCrossRef
26.
United Nations Scientific Committee on the Effects of Atomic Radiation: 2000 Report to the General Assembly, with Annexes. Ionizing radiation: Sources and Biological Effects. 2000, New York: United Nations
27.
Howe GR, McLaughlin J: Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivor study. Radiat Res. 1996, 145: 694-707.PubMedCrossRef
28.
Boice JD, Preston D, Davis FG, Monson RR: Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res. 1991, 125: 215-222.CrossRef
29.
Doody MM, Lonstein JE, Stovall M, Hacker DG, Luckyanov N, Land CE: Breast cancer mortality after diagnostic radiography. Spine. 2000, 25: 2052-2063. 10.1097/00007632-200008150-00009.PubMedCrossRef
30.
Hildreth NG, Shore RE, Dvoretsky PM: The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med. 1989, 321: 1281-1284.PubMedCrossRef
31.
Lundell M, Mattsson A, Karlsson P, Holmberg E, Gustafsson A, Holm L-E: Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiat Res. 1999, 151: 626-632.PubMedCrossRef
32.
Modan B, Chetrit A, Aldandary E, Katz L: Increased risk of breast cancer after low-dose irradiation. Lancet. 1989, 8639: 629-631. 10.1016/S0140-6736(89)92140-5.CrossRef
33.
Mattsson A, Rudén B-I, Hall P, Wilking N, Rutqvist LE: Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst. 1993, 85: 1679-1685.PubMedCrossRef
34.
Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B: Breast cancer among women given x-ray therapy for acute postpartum mastitis. J Natl Cancer Inst. 1986, 77: 689-696.PubMed
35.
Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT: High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003, 21: 4386-4394. 10.1200/JCO.2003.11.059.PubMedCrossRef
36.
Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L: Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004, 141: 590-597.PubMedCrossRef
37.
Metayer C, Lynch CF, Clarke A, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van 't Veer MB, Curtis RE, et al: Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol. 2000, 18: 2435-2443.PubMed
38.
Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000, 18: 498-509.PubMed
39.
Storm HH, Andersson M, Boice JD, Blettner M, Stovall M, Mouridsen HT, Dombernowsky P, Rose C, Jacobsen A, Pedersen M: Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst. 1992, 84: 1245-1250.PubMedCrossRef
40.
Boice JD, Harvey EB, Blettner M, Stovall M, Flannery JT: Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992, 326: 781-785.PubMedCrossRef
41.
van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van 't Veer MB, Noordijk EM, Crommelin MA, Aleman BMP, Broeks A, Gospodarowics M, et al: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's Disease. J Natl Cancer Inst. 2003, 95: 971-980.PubMedCrossRef
42.
United Nations Scientific Committee on the Effects of Atomic Radiation: Sources, Effects, and Risks of Ionizing Radiation: 1994 Report to the General Assembly with Scientific Annexes. 1994, New York: UNSCEAR
43.
Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, Tokuoka S: Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1990. Radiat Res. 2003, 160: 707-717.PubMedCrossRef
44.
BEIR: The Effects on Populations of Exposure to Low Levels of Ionizing Radiation. Report of the Advisory Committee on the Biological Effects of Ionizing Radiations (BEIR). 1980, Washington DC: National Academy of Sciences, 136-145.
45.
Preston DL, Mattson AM, Holmberg E, Shore R, Hildreth N, Boice JD: Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002, 158: 220-235.PubMedCrossRef
46.
Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, et al: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003, 290: 465-475. 10.1001/jama.290.4.465.PubMedCrossRef
47.
Howard BA, Gusterson BA: Human breast development. J Mamm Gland Biol Neoplasia. 2002, 5: 119-137. 10.1023/A:1026487120779.CrossRef
48.
Russo J, Russo IH: Toward a unified concept of mammary carcinogenesis. Prog Clin Biol Res. 1997, 396: 1-16.PubMed
49.
Moolkavgar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 1980, 65: 559-569.
50.
Delongchamp RR, Mabuchi K, Yoshimoto Y, Preston DL: Cancer mortality among atomic bomb survivors exposed in utero or as young children, October 1950–May 1992. Radiat Res. 1997, 147: 385-395.PubMedCrossRef
51.
Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A, Langmark F, Lanning M, Moller T, Tulinius H: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol. 1996, 14: 1442-1446.PubMed
52.
Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996, 334: 745-751. 10.1056/NEJM199603213341201.PubMedCrossRef
53.
Percy CL, Smith MA, Linet M, Gloeckler Ries LA, Friedman DL: Lymphomas and reticuloendothelial neoplasms. In Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. NIH Pub. No. 99-4649. Edited by: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL. 1999, Bethesda MD: National Cancer Institute, SEER Program, 36-42.
54.
Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL: Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001, 93: 618-629. 10.1093/jnci/93.8.618.PubMedCrossRef
55.
Yasui Y, Liu Y, Neglia JP, Friedman DL, Bhatia S, Meadows AT, Diller LR, Mertens AC, Whitton J, Robison LL: A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003, 158: 1108-1113. 10.1093/aje/kwg278.PubMedCrossRef
56.
Hancock SL, Tucker MA, Hoppe RT: Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993, 85: 25-31.PubMedCrossRef
57.
Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002, 100: 1989-1996. 10.1182/blood-2002-02-0634.PubMedCrossRef
58.
Abrahamsen AF, Andersen A, Nome O, Jacobsen AB, Holte H, Abrahamsen F, Kvaløy S: Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol. 2002, 13: 1786-1791. 10.1093/annonc/mdf289.CrossRef
59.
Wahner-Roedler DL, Nelson DF, Croghan IT, Achenbach SJ, Crowson CS, Hartmann LC, O'Fallon WM: Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience. Mayo Clin Proc. 2003, 78: 708-715.PubMedCrossRef
60.
McGregor DH, Land CE, Choi K, Tokuoka S, Wakabayashi T, Beebe GW: Breast cancer incidence among atomic bomb survivors, Hiroshima and Nagasaki, 1950–69. J Natl Cancer Inst. 1977, 59: 799-811.PubMed
61.
Tokunaga M, Norman JE, Asano M, Tokuoka S, Ezaki H, Nishimori I, Tsuji Y: Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. J Natl Cancer Inst. 1979, 62: 1347-1359.PubMed
62.
Tokunaga M, Land CE, Yamamoto T, Asano M, Tokuoka S, Ezaki H, Nishimori I: Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1980. Radiat Res. 1987, 112: 243-272.PubMedCrossRef
63.
Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S: Incidence of female breast cancer among atomic bomb survivors, 1950–1985. Radiat Res. 1994, 1338: 209-223.CrossRef
64.
Chen J, Lee J, Tsodikov A, Smith L, Gaffney DK: Does radiotherapy around the time of pregnancy for Hodgkin's disease modify the risk of breast cancer?. Int J Radiation Oncology Biol Phys. 2004, 58: 1474-1479. 10.1016/j.ijrobp.2003.09.018.CrossRef
65.
Boice JD, Stone BJ: Interaction between radiation and other breast cancer factors. In: Late biological effects of ionizing radiation. In Proceedings of the Symposium on Late Biological Effects of Ionizing Radiation: Vienna, Austria. 1978, Vienna: International Atomic Energy Agency, 1: 231-249. 13–17 March 1978
66.
van Bekkum DW, Broerse JJ: Induction of mammary tumors by ionising radiation. Radiat Environ Biophys. 1991, 30: 217-220.PubMedCrossRef
67.
Shellabarger CJ: Modifying factors in rat mammary gland carcinogenesis. In Biology of Radiation Carcinogenesis. Edited by: Yuhas J, Tennant RW, Regan JR. 1976, New York: Raven Press, 31-43.
68.
Holtzman S, Stone JP, Shellabarger CJ: Radiation-induced mammary carcinogenesis in virgin, pregnant, lactating and post-lactating rats. Cancer Res. 1982, 42: 50-53.PubMed
69.
Bartstra RW, Bentvelzen PA, Zoetelief J, Mulder AH, Broerse JJ, van Bekkum DW: Induction of mammary tumors in rats by single-dose gamma irradiation at different ages. Radiat Res. 1998, 150: 442-450.PubMedCrossRef
70.
Inano H, Suzuki K, Ononda M, Yamanouchi H: Susceptibility of fetal, virgin, pregnant, and lactating rats for the induction of mammary tumors by gamma rays. Radiat Res. 1996, 145: 708-713.PubMedCrossRef
71.
Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA. 1995, 92: 3650-3657.PubMedPubMedCentralCrossRef
72.
Shimada Y, Yasukawa-Barnes J, Kim RY, Gould MN, Clifton KH: Age and radiation sensitivity of rat mammary clonogenic cells. Radiat Res. 1994, 137: 118-123.PubMedCrossRef
73.
Shellabarger CJ: A comparison of rat mammary carcinogenesis following total-body irradiation at different ages. In Abstracts of papers presented at the 5th International Congress of Radiation Research. 1974, 103-
74.
Albert RE, Benjamin SA, Shukla R: Life span and cancer mortality in the Beagle dog and humans. Mech Aging Dev. 1994, 74: 149-159. 10.1016/0047-6374(94)90086-8.PubMedCrossRef
75.
Benjamin SA, Lee AC, Angleton GM, Saunders WJ, Keefe TJ, Mallinckrodt CH: Mortality in beagles irradiated during prenatal and postnatal development. II. Contribution of benign and malignant neoplasia. Radiat Res. 1998, 150: 330-348.PubMedCrossRef
76.
Preston DL, Pierce DA, Shimizu Y, Ron E, Mabuchi K: Dose response and temporal patterns of radiation-associated solid cancer risks. Health Phys. 2003, 85: 43-46. 10.1097/00004032-200307000-00010.PubMedCrossRef
77.
Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, Tokunaga M: A case-control interview study among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes Control. 1994, 5: 167-176.PubMedCrossRef
78.
Shore RE, Woodard ED, Hempelmann LH, Pasternack BS: Synergism between radiation and other risk factors for breast cancer. Prev Med. 1980, 9: 815-820. 10.1016/0091-7435(80)90024-9.PubMedCrossRef
79.
Holmberg E, Holm LE, Lundell M, Mattsson A, Wallgren A, Karlsson P: Excess breast cancer risk and the role of parity, age at first childbirth and exposure to radiation in infancy. Br J Cancer. 2001, 85: 362-366. 10.1054/bjoc.2001.1868.PubMedPubMedCentralCrossRef
80.
van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000, 18: 487-497.PubMed
81.
Hill DA, Preston-Martin S, Ross RK, Bernstein L: Medical radiation, family history of breast cancer, and benign breast disease in relation to breast cancer risk in young women. Cancer Causes Control. 2002, 13: 711-718. 10.1023/A:1020201106117.PubMedCrossRef
82.
Petersen GM: Familial aggregation: sorting susceptibility from shared environment. J Natl Cancer Inst. 2000, 92: 1114-1115. 10.1093/jnci/92.14.1114.PubMedCrossRef
83.
Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002, 20: 3484-3494. 10.1200/JCO.2002.09.038.PubMedCrossRef
84.
Land CE, Tokunaga M, Tokuoka S, Nakamura N: Early-onset breast cancer in A-bomb survivors. Lancet. 1993, 342: 237-10.1016/0140-6736(93)92324-M.PubMedCrossRef
85.
Preston RJ: A consideration of the mechanisms of induction of mutations in mammalian cells by low doses and dose rates of ionizing radiation. Adv Radiat Biol. 1992, 16: 125-135.CrossRef
86.
Rothkamm K, Krüger I, Thompson LH, Löbrich M: Pathways of DNA double strand repair during the mammalian cell cycle. Mol Cell Biol. 2003, 23: 5706-5715. 10.1128/MCB.23.16.5706-5715.2003.PubMedPubMedCentralCrossRef
87.
Rothkamm K, Löbrich M: Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA. 2003, 100: 5057-5062. 10.1073/pnas.0830918100.PubMedPubMedCentralCrossRef
88.
Mohrenweiser HW, Wilson DM, Jones IM: Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res. 2003, 526: 93-125.PubMedCrossRef
89.
90.
Bennett LM: Breast cancer: Genetic predisposition and exposure to radiation. Mol Carcinogen. 1999, 26: 143-149. 10.1002/(SICI)1098-2744(199911)26:3<143::AID-MC2>3.0.CO;2-S.CrossRef
91.
Khanna KK: Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst. 2000, 92: 795-802. 10.1093/jnci/92.10.795.PubMedCrossRef
92.
Concannon P: ATM heterozygosity and cancer risk. Nat Genet. 2002, 32: 89-90. 10.1038/ng0902-89.PubMedCrossRef
93.
Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, et al: Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst. 2001, 93: 121-127. 10.1093/jnci/93.2.121.PubMedCrossRef
94.
Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ: ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000, 66: 494-500. 10.1086/302746.PubMedPubMedCentralCrossRef
95.
Bernstein JL, Bernstein L, Thompson WD, Lynch CF, Malone KE, Teitelbaum SL, Olsen JH, Anton-Culver H, Boice JD, Rosenstein BS, WECARE Study Collaborative Group, et al: ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. Br J Cancer. 2003, 89: 1513-1516. 10.1038/sj.bjc.6601289.PubMedPubMedCentralCrossRef
96.
Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, Malone KE, Lynch CF, Olsen JH, Anton-Culver H, et al: Study design: evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study. Breast Cancer Res. 2004, 6: R199-R214. 10.1186/bcr771.PubMedPubMedCentralCrossRef
97.
Weil MM, Kittrel FS, Yu Y, McCarthy M, Zabriskie RC, Ullrich RL: Radiation induces genomic instability and mammary ductal dysplasia in Atm heterozygous mice. Oncogene. 2001, 20: 4409-4411. 10.1038/sj.onc.1204589.PubMedCrossRef
98.
Carlomagno F, Chang-Claude J, Dunning AM, Ponder BA: Determination of the frequency of the common 657Del5 Nijmegen breakage syndrome mutation in the German population: no association with risk of breast cancer. Genes Chromosomes Cancer. 1999, 25: 393-395. 10.1002/(SICI)1098-2264(199908)25:4<393::AID-GCC12>3.0.CO;2-8.PubMedCrossRef
99.
The International Nijmegen Breakage Syndrome Study Group (INBSG): Nijmegen breakage syndrome. Arch Dis Child. 2000, 82: 400-406. 10.1136/adc.82.5.400.CrossRef
100.
International Commission on Radiological Protection: Genetic Susceptibility to Cancer. ICRP publication 79. Edited by: Valentin J. 1998, Oxford: Pergamon
101.
Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004, 96: 357-363.PubMedCrossRef
102.
Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF, et al: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997, 278: 1262-1267. 10.1001/jama.278.15.1262.PubMedCrossRef
103.
Moll AC, Imhof SM, Schouten-van Meeteren AYN, Kuik DJ, Hofman P, Boers M: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997. Opthalmology. 2001, 108: 1109-1114. 10.1016/S0161-6420(01)00562-0.CrossRef
104.
Limacher J-M, Frebourg T, Natarajan-Ame S, Bergerat JP: Two metachronous tumors in the radiotherapy fields of a patient with Li–Fraumeni Syndrome. Int J Cancer Radiat Oncol Invest. 2001, 96: 238-242.CrossRef
105.
Xia F, Powell SN: The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol. 2002, 12: 296-304. 10.1053/srao.2002.35250.PubMedCrossRef
106.
Nieuwenhuis B, Van Assen-Bolt AJ, Van Waarde-Verhagen MA, Sijmons RH, Van der Hout AH, Bauch T, Streffer C, Kampinga HH: BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. Int J Radiat Biol. 2002, 78: 285-295. 10.1080/09553000110097974.PubMedCrossRef
107.
Leong T, Whitty J, Keilar M, Mifsud S, Ramsay J, Birrell G, Venter D, Southey M, McKay M: Mutation analysis of BRCA1 and BRCA2 cancer predisposition genes in radiation hypersensitive cancer patients. Int J Radiat Oncol Biol Phys. 2000, 48: 959-965. 10.1016/S0360-3016(00)00728-8.PubMedCrossRef
108.
Gaffney DK, Hemmersmeier J, Holden J, Marshall J, Smith LM, Avizonis V, Tran T, Neuhausen SL: cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Int J Radiat Oncol Biol Phys. 2001, 49: 539-546. 10.1016/S0360-3016(00)01481-4.PubMedCrossRef
109.
Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BAJ, Pharoah PDP, et al: Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet. 2002, 11: 1399-1407. 10.1093/hmg/11.12.1399.PubMedCrossRef
110.
Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, Hauptmann M, Mohan AK, Yoshinaga S, Hill DA, Tarone R, et al: Cancer incidence in the US radiologic technologists health study, 1983–1998. Cancer. 2003, 97: 3080-3089. 10.1002/cncr.11444.PubMedCrossRef
111.
Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP: Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer. 2004, 4: 9-10.1186/1471-2407-4-9.PubMedPubMedCentralCrossRef
Metadaten
Titel
Radiation and breast cancer: a review of current evidence
verfasst von
Cécile M Ronckers
Christine A Erdmann
Charles E Land
Publikationsdatum
01.02.2004
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2004
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr970

Weitere Artikel der Ausgabe 1/2004

Breast Cancer Research 1/2004 Zur Ausgabe

Research article

Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast

Research article

Polychlorinated biphenyls, cytochrome P450 1A1 (CYP1A1) polymorphisms, and breast cancer risk among African American women and white women in North Carolina: a population-based case-control study

Article selection

Articles selected in November 2004

Commentary

New highlights on stroma–epithelial interactions in breast cancer

Research article

Letrozole sensitizes breast cancer cells to ionizing radiation

Research article

Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise